Colorado-based MicroRNA upstart MiRagen Therapeutics just raised $8.5 million of a potential $20 million round, according to a regulatory filing. Its miRNA drugs are focused on correcting a number of cardiovascular, blood malignancies and fibrosis.
This form of RNA helps regulate gene expression – so modified miRNAs can help diseases change their course of pathology. For instance, a recent study with Yale University found its miRNA therapeutics could reverse pulmonary fibrosis in mouse models.
“The mimic, when injected into the blood, goes to the lung and it has a sustained effect. We are very impressed that it can reverse fibrosis, not only prevent it,” Yale researcher Naftali Kaminski said in a statement.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The company’s most recent fundraise was last June when it raised $7 million. The company didn’t respond to calls about how this most recent funding round will be used.
